Next Article in Journal
Plasma in Cancer Treatment
Previous Article in Journal
Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 12
Issue 9
10.3390/cancers12092616
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Comprehensive Analysis of MEN1 Mutations and Their Role in Cancer

by
Devi D. Nelakurti
1,†,
Amrit L. Pappula
2,†,
Swetha Rajasekaran
3,
Wayne O. Miles
4 and
Ruben C. Petreaca
5,*
1
Biomedical Science Undergraduate Program, The Ohio State University Medical School, Columbus, OH 43210, USA
2
Computer Science and Engineering Undergraduate Program, The Ohio State University, Columbus, OH 43210, USA
3
Department of Molecular Genetics, The Ohio State University, Columbus, OH 43210, USA
4
Department of Cancer Biology and Genetics, The Ohio State University Medical School, Columbus, OH 43210, USA
5
Department of Molecular Genetics, The Ohio State University, Marion, OH 43302, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cancers 2020, 12(9), 2616; https://doi.org/10.3390/cancers12092616
Submission received: 30 July 2020 / Revised: 4 September 2020 / Accepted: 10 September 2020 / Published: 14 September 2020
(This article belongs to the Section Cancer Informatics and Big Data)
Browse Figures
Versions Notes

Abstract

:

Simple Summary

Cancers are characterized by accumulation of genetic mutations in key cell cycle regulators that alter or disable the function of these genes. Such mutations can be inherited or arise spontaneously during the life of the individual. The MEN1 gene prevents uncontrolled cell division and it is considered a tumor suppressor. Inherited MEN1 mutations are associated with certain parathyroid and pancreatic syndromes while spontaneous mutations have been detected in cancer cells. We investigated whether inherited mutations appear in cancer cells which would suggest that patients with parathyroid and pancreatic syndromes have a predisposition to develop cancer. We find a weak correlation between the spectrum of inherited mutations and those appearing spontaneously. Thus, inherited MEN1 mutations may not be a good predictor of tumorigenesis.

Abstract

MENIN is a scaffold protein encoded by the MEN1 gene that functions in multiple biological processes, including cell proliferation, migration, gene expression, and DNA damage repair. MEN1 is a tumor suppressor gene, and mutations that disrupts MEN1 function are common to many tumor types. Mutations within MEN1 may also be inherited (germline). Many of these inherited mutations are associated with a number of pathogenic syndromes of the parathyroid and pancreas, and some also predispose patients to hyperplasia. In this study, we cataloged the reported germline mutations from the ClinVar database and compared them with the somatic mutations detected in cancers from the Catalogue of Somatic Mutations in Cancer (COSMIC) database. We then used statistical software to determine the probability of mutations being pathogenic or driver. Our data show that many confirmed germline mutations do not appear in tumor samples. Thus, most mutations that disable MEN1 function in tumors are somatic in nature. Furthermore, of the germline mutations that do appear in tumors, only a fraction has the potential to be pathogenic or driver mutations.

1. Introduction

The tumor suppressor gene MEN1 encodes MENIN, a scaffold protein with diverse functions in cell cycle regulation, DNA repair, and gene expression [1,2]. The crystal structure of MENIN shows that it contains four major domains: an N-terminal domain (NTD), two middle thumb and palm domains, and a C-terminus Fingers domain [3,4] (Figure 1A). A central cavity in the thumb and palm domains contains several TPR (tetracopeptide repeat) motifs. Such motifs are involved in intra- and inter-molecular interactions [5] and have been proposed to facilitate MENIN interaction with various proteins. Several other structural motifs have also been identified and are discussed elsewhere [3,4]. Three nuclear localization sequences (NLS1, NLS2, NLS3) [6,7,8] and two nuclear exit sequences (NES1, NES2) have been identified [9] which show that MENIN shuttles in and out of the nucleus. MENIN interacts with a plethora of proteins [10,11] (Figure 1B). These MENIN interacting proteins function in gene expression regulation, cell cycle progression, DNA damage repair, and a variety of other processes [3,4,9,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28] (Table 1). Several other interactions have been reviewed elsewhere [2]. Mapping these MENIN interacting proteins to the MENIN sequence shows that most bind the palm and fingers domains (Figure 1B).
Mutations in this gene were first identified in the multiple endocrine neoplasia type 1 syndrome [29,30]. Subsequent analysis revealed that MEN1 alterations are also found in a subset of pancreatic endocrine tumors [31,32,33] and pituitary adenomas [34], as well as several other cancers [35,36]. In addition to its independent function, MEN1 also interacts with the lysine methyltransferase KMT2A (previously MLL1), and this interaction contributes to the oncogenic properties of KMT2A [37,38,39]. KMT2A is a proto-oncogene frequently activated by chromosomal re-arrangements and acts as genetic driver in a number of leukemias [40].
MEN1 mutations can be inherited (germline or hereditary) or be somatic [41]. Inherited mutations are autosomal dominant [42] and, rather than focusing on key residues, appear equally distributed along the coding sequence [29,41,42,43,44,45,46]. Similarly, analysis of over 17,000 somatic mutations within MEN1 found that the vast majority of these mutations were distributed more or less evenly throughout the entire coding region [1]. This analysis did, however, identify 9 amino acid positions with a higher mutation frequency (hotspots), suggesting that a bias for key residues may exist.
Mutations within MEN1 fall into several categories. A significant number of both germline and somatic mutations are frameshift and non-sense that produce truncated proteins of various sizes [42,47]. As MENIN is a scaffold protein, N-terminal mutations of this type are predicted to severely affect protein function. A large number of missense mutations have also been identified, while InDels (insertions and deletions) and splice site variants represent the smallest fraction of mutations found.
Not all inherited mutations show the same level of cancer penetrance. Several studies have investigated the degree with which germline mutations lead to cancer phenotypes [48,49,50,51,52,53,54,55,56]. Early phylogenetic studies showed that inherited MEN1 mutations are most likely to be associated with tumors of the parathyroid, pancreas, and pituitary gland [57]. Other tumor types within additional tissues were also found at significantly lower frequencies [58]. The goal of this study was to investigate whether MEN1 germline mutations appear in cancer cells, which would suggest that they predispose patients to cancer.
The Catalogue of Somatic Mutations in Cancer (COSMIC) (https://cancer.sanger.ac.uk/cosmic) has archived MEN1 mutations that have been reported in sequenced cancer genomes [59]. To determine whether reported germline mutations have been detected or are over-represented in cancer genomes, we carried out a pan-cancer correlation study between the COSMIC data and germline mutations reported on NCBI ClinVar (https://www.ncbi.nlm.nih.gov/clinvar). From this analysis, we found that only a subset of MEN1 germline mutations are found in tumors, suggesting that the mutations likely contribute to clinical pathologies rather than to neoplasia.

2. Materials and Methods

An Excel file with all MEN1 COSMIC mutations was downloaded from https://cancer.sanger.ac.uk/cosmic (version 91, hg38). Patient sample data was collected from the entire COSMIC database to capture the full tumor spectrum. COSMIC deposits both primary patient data obtained from the National Institutes of Health (NIH) The Cancer Genome Atlas (TCGA) project, as well as cell line data from the Cell Lines Project. The tumor composition of the COSMIC database is accurately described at the above website and within the downloaded COSMIC mutation file for MEN1 [59]. The COSMIC file also lists PubMed IDs for most mutations. These IDs were used to extract references listed in Table S1.
Pathogenic germline mutations were first extracted from Variation Viewer (https://www.ncbi.nlm.nih.gov/variation/view) and then were manually checked against ClinVar (https://www.ncbi.nlm.nih.gov/clinvar) data to ensure that they were reported to be germline and pathogenic (e.g., reported to cause various thyroid, parathyroid, pancreatic, or pituitary syndromes). ClinVar is updated constantly with investigator submitted mutations. The data presented in this manuscript is up to date as of July 26, 2020 (Table S2). Comparisons between ClinVar and COSMIC were made manually.
Protein alignments of the various MENIN isoforms were generated using COBALT (https://www.ncbi.nlm.nih.gov/tools/cobalt/re_cobalt.cgi) [60].
Graphs and statistics were performed with SPSS (version 25) under Ohio State University (OSU) license. The statistical analysis for the mutations were performed using the online Cancer-Related Analysis of Variants Toolkit (CRAVAT) software package [61,62,63,64]. The input tables (Table S3) contained variants obtained from COSMIC (MEN1_COSMIC_CRAVAT_INPUT) or directly from the NIH TCGA repository (MEN1_TCGA_CRAVAT_INPUT). Most of the TCGA data is contained within the COSMIC file, but some values are missing as COSMIC only updates the website periodically. The Cancer-Specific High Throughput Annotation of Somatic Mutations (CHASM) and Variant Effect Scoring Tool (VEST) analysis were both performed using the default parameters of the tool. The output (Tables S4 and S5) obtained from this tool include the CHASM score and a VEST score that indicate the likelihood of a mutation being a potential cancer driver and pathogenic, respectively. In our analysis, all mutations with a Benjamini-Hochberg qVal were considered to be significant.
All diagrams and figures were made in Photoshop. Lollipop figures were made as previously described [65]. Frameshift and indel variants that appear at same position are listed only once in the main text figures (e.g., I85fs represents all I85Yfs*32, I85Sfs*33, I85Lfs*35) to decrease crowding, but the exact mutation parameters are given in Tables. If a frameshift mutation introduces a stop codon, this is indicated by an asterisk (*).

3. Results and Discussion

3.1. MEN1 and MENIN

The MEN1 gene contains 9 introns and 10 exons [43,66]. Several transcript variants and protein isoforms have been identified (Table 2) that are largely generated by alternative splicing (Figure S1) [67,68,69]. Reference genomic and amino acids sequences for alternatively spliced genes is a matter of some debate. The Human Genome Variation Society (www.hgvs.org) [70] proposes using the Locus Reference Genomic (LRG) format [71,72]. An LRG database has been compiled with the standard reference for several genes (http://www.lrg-sequence.org/search/?query=*), and the proposed standard for MEN1 is transcript variant 1 (2785bp) and protein isoform 1 (615 amino acids) (Table 2). We suggest that the LGR system of numbering amino acids be used when describing MEN1 and MENIN.
Isoform 2 has been described extensively in the literature, yet the major transcript reported on COSMIC is e1E (ENST00000337652.5) which is 3179 bases long and is translated into isoform 1 (Table 2). Both COSMIC and ClinVar databases list mutations by transcript variant. This means that, depending on which variant was analyzed, the listed position of the mutation (amino acid number) may differ even though the same amino acid has been changed. For example, S160 in isoform 1 is the same amino acid as S155 in isoform 2 (Figure S1), and, therefore, it may be listed as two independent mutations on COSMIC (S160 and S155) when, in fact, they are the same. To prevent over-counting such mutations and present a more unifying literature reference, we aligned protein isoforms. In the analysis presented here, mutations are only listed more than once if they were independently identified in two or more samples. The data presented here is for the 615 amino acid protein isoform 1 of MEN1. The five additional amino acids within this isoform (WSPVG) have no recorded mutations (Figure S1).

3.2. MEN1 Mutation Distribution

The COSMIC database reports a total of 1012 MEN1 mutations detected in 29 tumor types (Figure 2A, Table S1). For a subset of mutations, the tissue of origin was not specified, so this data was labeled as “Not Specified” (Figure 2A). As expected, a higher incidence of MEN1 mutations are found in the pancreatic and parathyroid tumors. Interestingly, a significant number of MEN1 mutations are also found in tumors of the breast, large intestine, and lung (Figure 2A). The majority of the mutations within MEN1 are substitution/missense and/or frameshifts, but non-sense, indels, splice site/intronic, and synonymous mutational events were also identified (Figure 2B, Table S1).
Previous reports showed that MEN1 mutations are distributed evenly over the protein regions, suggesting that there is limited mutational selection pressure on conserved residues or domains within MEN1 [1,2]. To test whether this is true, we used the Kolmogorov–Smirnov test for uniformity (Figure S2) [73] to determine whether the germline (ClinVar) and somatic (COSMIC) mutations were evenly distributed relative to each other. For this analysis, we included only substitutions, nonsense, frameshift, and InDels as they can be directly mapped to the gene (808 out of 1202). The additional 374 mutations, which include intronic, splice site, and synonymous mutations, are discussed in later sections. From this analysis, we found that, of the 808 total COSMIC substitutions, non-sense, frameshift, and InDel mutations, 548 (67.8%) mapped to unique Open Reading Frame (ORF) positions; the remaining 32.2% mutations mapped multiple times at the same position in different samples (e.g., formed hotspots) (Figure 3A, right panel). Using ClinVar, we identified 197 germline mutations (Figure 3A, left panel, Table S2). Contrastingly, while the majority of COSMIC mutations are substitution/missense, germline mutations within the ClinVar dataset are enriched for frameshift disruptions. These results suggested that somatic and germline mutations within MEN1 may significantly differ.
The Kolmogorov–Smirnov test for uniformity (Figure S2) shows that ClinVar mutations do distribute evenly over the entire protein [74] (p = 0.178) (Figure 3B). Although not statistically significant, several small mutational clusters can be seen around amino acids 100, 140, and 420, respectively. In contrast, COSMIC mutations tend to cluster over key protein domains (p = 1.5 × 10 −4) (Figure 3B). In particular, COSMIC mutations tend to cluster in the NTD and thumb domains of MEN1. Remarkably, none of these clusters correlate with the ClinVar clusters. Thus, this analysis shows that the distribution of somatic mutations of MEN1 in tumors poorly correlate with the distribution of germline mutations.
Next, we graphed all of the COSMIC mutations to identify residues that have dis-proportionately high levels of mutations. This identified three major hotspots. Two of these recurrent mutations resulted in frameshifts within MEN1 (I85fs and R521fs) and have been previously identified [1] (Figure 3C). As the I85 frameshift mutation introduces a very early termination codon, we predict that this mutation would severely limit the production of this protein isoform. The remaining recurrent mutation, T546A (T541A in isoform 2), is very close to the R521fs mutation, suggesting that disruption of the C-terminal of MEN1 may be important for tumorigenesis (Figure 3C).
Non-sense and frameshift mutations are most likely to affect critical functions of MEN1 because they cause truncations or affect the codon reading frame. While the non-sense mutations are evenly distributed for both COSMIC and ClinVar, the amino acid substitutions and frameshift mutations are not (Figure S3). Remarkably, indels are rare in ClinVar data, but they do appear in COSMIC at low frequency. ClinVar reports 20 splice site variants, of which only 7 are also detected in COSMIC tissues (Tables S1 and S2). Of the 197 total ClinVar mutations, only 78 are detected in somatic tissues. Collectively, these data suggest that the majority of germline MEN1 mutations are unlikely to contribute to the neoplasia. We discuss some of these mutations in the next sections.
Synonymous mutations were identified in both germline and somatic tissues. These mutations are often excluded as they do not alter the protein sequence. However, recent evidence shows that synonymous mutations may affect RNA splicing and mRNA stability [75]. We therefore tested the conservation of synonymous mutations within MEN1 and found no overlap between synonymous mutations identified in COSMIC or ClinVar (Tables S1 and S2).

3.3. Germline MEN1 Mutations in Pancreatic, Parathyroid, Thyroid, Pituitary, and Thymus Tissues

We first analyzed the MEN1 germline mutations in tissues that MEN1 mutations have been reported to contribute to cancer predisposition, such as the pancreas and the parathyroid. Less common affected tissues, such as the thyroid, thymus, and the pituitary, were also included in this analysis. From this profiling, we identified 3 amino acid substitutions, 14 non-sense mutations, 5 splice variants (all upper panel), 27 frameshift mutations (lower panel), and one indel (lower panel) with MEN1 (Figure 4A).
While non-sense and frameshift mutations are expected to produce strong phenotypes, point mutations are more likely to affect specific functions. To determine the significance of the point mutations with MEN1, we used the Cancer-Related Analysis of Variants Toolkit (CRAVAT) [61]. This biostatistics tool determines statistical significance for two parameters: 1) the probability of the alteration being a driver mutation given by the CHASM (Cancer-Specific High Throughput Annotation of Somatic Mutations) algorithm [63] and 2) the likelihood that the mutation is pathogenic determined by VEST (Variant Effect Scoring Tool) algorithm [62,64] (Tables S4 and S5). CHASM can only analyze amino acid substitutions, while VEST can analyze any mutation. For this analysis, we set a cut-off for statistical significance of a p < 0.05 and a False Discovery Rate (FDR) of 0.1. These metrics were selected to account for the small sample size. Using this statistical package, we found that almost all mutations within MEN1 are significant in our VEST analysis, and the two exceptions are: P325L and W476* (Figure 4B, left panel). We utilized CHASM to calculate the potential of each mutation to be a driver event and found all three point mutations, L22R, P325L, and D423N, to be statistically significant driver mutations (Figure 4B, right panel).
To examine the possible mechanisms of the mutations and the tissues of origins, we studied the existing MEN1 literature. The L22R mutation was only found in pancreatic tumors, suggesting it may have strong tissue specific effects. This mutation is predicted to limit the capacity of MEN1 to restrict the periodic expression of Cyclin B2 and partially disable cell cycle arrest at the G2/M checkpoint [76]. In addition, this mutation is required for interaction with PRMT5 [21] and, given the strong requirement of MENIN and PRMT5 in promoting pancreatic cell proliferation [77], this finding suggests that L22R may contribute to cellular growth. The P325L mutation (P320L in isoform 2) sits right at the boundary of the palm and fingers domains was only identified in parathyroid tumors [46,78]. This mutation is predicted to significantly decrease the protein stability of MENIN by targeting the protein for degradation [79]. The D423N mutant (D418N in isoform 2) is also exclusively found in parathyroid cancers [80,81]. The molecular consequence of this mutation is unexplored.
The frameshift mutation I85fs (I85Yfs*32, I85Sfs*33, I85Lfs*35) is one of the most prevalent germline mutations both in parathyroid, thyroid, and pancreatic cancers, as well as other cancer types (also see Figure 5 and Figure 6) [1,41,82,83,84,85,86,87,88,89,90,91,92,93,94,95]. Although this mutation has been previously shown to be a hotspot, only one mutational event was identified, c.249_252delGTCT [1]. In our analysis, we found that this position is characterized by at least three types of frameshifts caused by deletions and insertions (Table S1). Each of these frameshifts are predicted to terminate the translation of the MEN1 RNA within 32–35 amino acids, thus producing a truncated and/or unstable protein. Considering that several frameshift mutations occur within the same region, it is not immediately clear why the I85fs mutation should occur at higher frequency than the others. This mutation occurs within the center of exon 2 within a region that is characterized by the repeated amino acids Ile-Ile-Ala-Ala (atc atc cgc cgc), and we speculate that this may cause higher rates of DNA polymerase slippage. At least one report shows that no minimum nucleotide repeats are required for DNA polymerase slippage [96].

3.4. Germline MEN1 Mutations Penetrant in other Cancers

Next, we investigated the frequency of germline MEN1 mutations in all tumor types. From this analysis, 44 germline mutations were identified (Figure 5A). For comparison and visualization, we also include mutations shown in Figure 4A, and only mutations that have significant CHASM or VEST p-values are labeled. The CRAVAT analysis shows that most mutations are likely to be pathogenic (Figure 5B, left panel). In contrast to the mutations enriched in tumors from MEN1 sensitive tissues (parathyroid, pancreas), none of the point mutations found in other tumors types are driver mutations based on our CHASM criteria (Figure 5B, right panel). Although L228P and E260K both have CHASM p-values just below 0.05 (0.0494 and 0.0416, respectively), their FDR scores are well outside statistical significance.
Several highly enriched and significant truncating mutations appear within the thumb region of MEN1 (aa 98-188). The Q171* (VEST p-value = 0.0024) non-sense mutation is present in nine COSMIC samples (Figure 4A, Figure 5A) and is also detected in primary cancer tissues (see Figure 6A). In addition to our analysis, this mutation has also been identified in a metastatic cancer screen [82], two breast cancer mutation analysis studies [97,98], and adrenal cortical adenoma [99]. A frameshift mutation (Q171Rfs*19) has also been identified in parathyroid tumors [100]. The R98* mutation (VEST p-value = 0.0069) was detected in 7 samples in our analysis and has been identified in several tumors [82,84,101,102,103]. A point mutant (R98Q) and a frameshift variant (R98Efs*21) has also been detected [104]. The W126* non-sense mutation (VEST p-value = 0.0024) that is positioned closely to the highly mutated Q171 residue is also reported five times in COSMIC data. It, too, has been identified in metastatic [82] and breast [105] cancers, as well as pancreatic [83] and adrenal [106] tumors. One frameshift mutation at this position (W126fs*23) was identified in metastatic and thyroid cancers [82,107], and a W126G point mutation at this location has been reported [85]. Q141* (VEST p-value = 0.0095) and R108* (VEST p-value = 0.0154) are two other truncations in this region that appear with higher frequency in various cancers [82,89,108,109,110,111,112]. These examples suggest that our analysis has identified recurrent and important MEN1 alleles that contribute to the tumorigenic process. Why these five truncating mutations within the same region should be more penetrant than others remains unknown, but it suggests that mutations in this region may destabilize broader functions of MENIN that manifest in multiple cancer types.

3.5. MEN1 Mutations in Primary Tumors

COSMIC provides an exhaustive collection of data from multiple sources. This includes reports from both TCGA samples that are derived from patient tumor samples, as well as non-TCGA resources, which may include cultured cell lines. We next wanted to focus solely on the mutational spectrum of MEN1 in patient tumors. For this, we accessed reported MEN1 mutations directly from the NIH TCGA website. These data include a few other mutations not reported in COSMIC version 91. This analysis identified 91 mutations within the MEN1 gene from TCGA primary tissues (Figure 6A).
We next tested the potential for each of these events to be driver mutations using CHASM, and, although some presented p-values below 0.05, we consider them not to be significant based on their high FDR scores (Figure 6B). Of these, only one similar mutation at A165 (CHASM p-value = 0.014, VEST p-value = 0.0032) was also found in the germline dataset. The W126S mutation does not have an FDR score below 0.3. In contrast, 57 pathogenic mutations were found to be statistically significant using VEST (Figure 6C). Unsurprisingly, most of the other mutations with VEST p-value below 0.05 are also unique to TCGA (Figure 6C). A small subset of these mutations has been reported as rare events in non-COSMIC datasets. These data strongly suggest that MEN1 mutations detected in patient tumor samples most likely appear spontaneously and are somatic in nature.
The two frameshift mutations forming the hotspot at position R521 (R521Gfs*43 VEST p = 0.0094 and R521Pfs*15 VEST p = 0.0102) (Figure 3C) [1] have also been found in germline tissues and have been detected 25 times in several cancers, including thyroid [113,114], parathyroid [41,100,102,103], colorectal [115,116,117,118], pancreatic [119], gastric [120,121], and lung [122], as well as other metastatic cancers [82] (Tables S1 and S2). Two other mutations at this locus (R521Q and R521W) that do not have significant CHASM or VEST value in our study have also been identified. R521 is positioned within a finger region between NLS1 and NLS3, and, although the exact role of these mutations is not known, the R521Gfs*43 likely disrupts the function of NLS3. The neighboring T546A (T541A in isoform 2) hotspot (CHASM p = 0.004, VEST p = 0.8887) appears in 24 samples [123,124] (Tables S1 and S2). This mutation, which has also been detected in germline tissues, appears to affect apoptosis [125]. The I85 hotspot is generated mainly by the I85Yfs*32, I85Sfs*33, I85Lfs*35, and I85V mutations and is discussed in the previous sections.

4. Conclusions

In this study, we showed that only a fraction of inherited MEN1 aberrations appear as somatic mutations in tumors. Although germline MEN1 mutations contribute to the clinical pathologies of the parathyroid, thyroid, and pancreatic syndromes, we find that very few contribute to neoplasia and cancer. As neither COSMIC nor TCGA contains inherited MEN1 mutant patient data, our analysis is limited to making predictions on the contribution of these events to tumorigenesis. However, as this is a pan cancer analysis it suggests that, if MEN1 germline mutations significantly contributed to cancer phenotypes, they would be detectable in various patient samples. As our analysis shows that only a small fraction of the mutations appears in tumors, we speculate that many MEN1 germline mutations do not drive neoplasia. We further show that, of the germline mutations that do appear in tumors, only a small fraction has the potential to be pathogenic or driver mutations. The clinical value of this data is to highlight the need for somatic testing of cancer patients with MEN1 disruptions, rather than, or at least in addition to, pedigree studies that focus on cancer pre-disposition syndromes.

Supplementary Materials

The following are available online at https://www.mdpi.com/2072-6694/12/9/2616/s1, Figure S1: Amino acid sequence alignment of various MENIN isoforms, Figure S2: Example of the Kolmogorov-Smirnov uniformity test statistic, Figure S3: Distribution of ClinVar and COSMIC mutations by type, Table S1: Summary of MEN1 mutations reported on COSMIC, Table S2: ClinVar confirmed pathogenic mutations, Table S3: CRAVAT input values, Table S4: CRAVAT output non-TCGA values, Table S5: CRAVAT output TCGA values.

Author Contributions

D.D.N. conceived the project and collected data; A.L.P. created most figures and contributed to data collection; S.R. calculated CHASM and VEST p values; R.C.P. wrote the first draft; R.C.P. and W.O.M. revised subsequent drafts. All authors have read and agreed to the published version of the manuscript.

Funding

Funding was provided by the Ohio State University James Comprehensive Cancer Center. SR is a James Comprehensive Cancer Center Pelotonia Fellow. This work was supported in part by grants from the Damon Runyon Cancer Research Found to WOM (51-18), a P30 award (CA016058) to OSU and a RO3 (CA223545) to RCP both from the National Cancer Institute, Bethesda, MD.

Acknowledgments

The authors thank James and Ellen Bazzoli for their generous donation to sponsor our laboratory space.

Conflicts of Interest

All authors declare no conflict of interest.

References

  1. Li, J.W.Y.; Hua, X.; Reidy-Lagunes, D.; Untch, B.R. MENIN loss as a tissue-specific driver of tumorigenesis. Mol. Cell. Endocrinol. 2018, 469, 98–106. [Google Scholar] [CrossRef]
  2. Matkar, S.; Thiel, A.; Hua, X. Menin: A scaffold protein that controls gene expression and cell signaling. Trends Biochem. Sci. 2013, 38, 394–402. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Huang, J.; Gurung, B.; Wan, B.; Matkar, S.; Veniaminova, N.A.; Wan, K.; Merchant, J.L.; Hua, X.; Lei, M. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 2012, 482, 542–546. [Google Scholar] [CrossRef]
  4. Murai, M.J.; Chruszcz, M.; Reddy, G.; Grembecka, J.; Cierpicki, T. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J. Biol. Chem. 2011, 286, 31742–31748. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Lamb, J.R.; Tugendreich, S.; Hieter, P. Tetratrico peptide repeat interactions: To TPR or not to TPR? Trends Biochem. Sci. 1995, 20, 257–259. [Google Scholar] [CrossRef]
  6. Guru, S.C.; Goldsmith, P.K.; Burns, A.L.; Marx, S.J.; Spiegel, A.M.; Collins, F.S.; Chandrasekharappa, S.C. Menin, the product of the MEN1 gene, is a nuclear protein. Proc. Natl. Acad. Sci. USA 1998, 95, 1630–1634. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. La, P.; Schnepp, R.W.; Clark, D.P.; Albert, C.S.; Hua, X. Tumor suppressor menin regulates expression of insulin-like growth factor binding protein 2. Endocrinology 2004, 145, 3443–3450. [Google Scholar] [CrossRef]
  8. La, P.; Desmond, A.; Hou, Z.; Silva, A.C.; Schnepp, R.W.; Hua, X. Tumor suppressor menin: The essential role of nuclear localization signal domains in coordinating gene expression. Oncogene 2006, 25, 3537–3546. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Cao, Y.; Liu, R.; Jiang, X.; Lu, J.; Jiang, J.; Zhang, C.; Li, X.; Ning, G. Nuclear-cytoplasmic shuttling of menin regulates nuclear translocation of {beta}-catenin. Mol. Cell. Biol. 2009, 29, 5477–5487. [Google Scholar] [CrossRef] [Green Version]
  10. Corbo, V.; Dalai, I.; Scardoni, M.; Barbi, S.; Beghelli, S.; Bersani, S.; Albarello, L.; Doglioni, C.; Schott, C.; Capelli, P.; et al. MEN1 in pancreatic endocrine tumors: Analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr. Relat. Cancer 2010, 17, 771–783. [Google Scholar] [CrossRef] [Green Version]
  11. Tsukada, T.; Nagamura, Y.; Ohkura, N. MEN1 gene and its mutations: Basic and clinical implications. Cancer Sci. 2009, 100, 209–215. [Google Scholar] [CrossRef] [PubMed]
  12. Scacheri, P.C.; Davis, S.; Odom, D.T.; Crawford, G.E.; Perkins, S.; Halawi, M.J.; Agarwal, S.K.; Marx, S.J.; Spiegel, A.M.; Meltzer, P.S.; et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet. 2006, 2, e51. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Kim, B.; Song, T.Y.; Jung, K.Y.; Kim, S.G.; Cho, E.J. Direct interaction of menin leads to ubiquitin-proteasomal degradation of beta-catenin. Biochem. Biophys. Res. Commun. 2017, 492, 128–134. [Google Scholar] [CrossRef] [PubMed]
  14. Jin, S.; Zhao, H.; Yi, Y.; Nakata, Y.; Kalota, A.; Gewirtz, A.M. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J. Clin. Investig. 2010, 120, 593–606. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Lemmens, I.H.; Forsberg, L.; Pannett, A.A.; Meyen, E.; Piehl, F.; Turner, J.J.; Van de Ven, W.J.; Thakker, R.V.; Larsson, C.; Kas, K. Menin interacts directly with the homeobox-containing protein Pem. Biochem. Biophys. Res. Commun. 2001, 286, 426–431. [Google Scholar] [CrossRef]
  16. Sowa, H.; Kaji, H.; Hendy, G.N.; Canaff, L.; Komori, T.; Sugimoto, T.; Chihara, K. Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2. J. Biol. Chem. 2004, 279, 40267–40275. [Google Scholar] [CrossRef] [Green Version]
  17. Agarwal, S.K.; Guru, S.C.; Heppner, C.; Erdos, M.R.; Collins, R.M.; Park, S.Y.; Saggar, S.; Chandrasekharappa, S.C.; Collins, F.S.; Spiegel, A.M.; et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999, 96, 143–152. [Google Scholar] [CrossRef] [Green Version]
  18. Heppner, C.; Bilimoria, K.Y.; Agarwal, S.K.; Kester, M.; Whitty, L.J.; Guru, S.C.; Chandrasekharappa, S.C.; Collins, F.S.; Spiegel, A.M.; Marx, S.J.; et al. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 2001, 20, 4917–4925. [Google Scholar] [CrossRef] [Green Version]
  19. Gang, D.; Hongwei, H.; Hedai, L.; Ming, Z.; Qian, H.; Zhijun, L. The tumor suppressor protein menin inhibits NF-kappaB-mediated transactivation through recruitment of Sirt1 in hepatocellular carcinoma. Mol. Biol. Rep. 2013, 40, 2461–2466. [Google Scholar] [CrossRef]
  20. Shi, K.; Parekh, V.I.; Roy, S.; Desai, S.S.; Agarwal, S.K. The embryonic transcription factor Hlxb9 is a menin interacting partner that controls pancreatic beta-cell proliferation and the expression of insulin regulators. Endocr. Relat. Cancer 2013, 20, 111–122. [Google Scholar] [CrossRef]
  21. Gurung, B.; Feng, Z.; Iwamoto, D.V.; Thiel, A.; Jin, G.; Fan, C.M.; Ng, J.M.; Curran, T.; Hua, X. Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome. Cancer Res. 2013, 73, 2650–2658. [Google Scholar] [CrossRef] [Green Version]
  22. Kim, H.; Lee, J.E.; Cho, E.J.; Liu, J.O.; Youn, H.D. Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res. 2003, 63, 6135–6139. [Google Scholar] [PubMed]
  23. Wu, G.; Yuan, M.; Shen, S.; Ma, X.; Fang, J.; Zhu, L.; Sun, L.; Liu, Z.; He, X.; Huang, D.; et al. Menin enhances c-Myc-mediated transcription to promote cancer progression. Nat. Commun. 2017, 8, 15278. [Google Scholar] [CrossRef]
  24. Jin, S.; Mao, H.; Schnepp, R.W.; Sykes, S.M.; Silva, A.C.; D’Andrea, A.D.; Hua, X. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res. 2003, 63, 4204–4210. [Google Scholar]
  25. Sukhodolets, K.E.; Hickman, A.B.; Agarwal, S.K.; Sukhodolets, M.V.; Obungu, V.H.; Novotny, E.A.; Crabtree, J.S.; Chandrasekharappa, S.C.; Collins, F.S.; Spiegel, A.M.; et al. The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene. Mol. Cell. Biol. 2003, 23, 493–509. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Gao, S.B.; Feng, Z.J.; Xu, B.; Wu, Y.; Yin, P.; Yang, Y.; Hua, X.; Jin, G.H. Suppression of lung adenocarcinoma through menin and polycomb gene-mediated repression of growth factor pleiotrophin. Oncogene 2009, 28, 4095–4104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Yokoyama, A.; Wang, Z.; Wysocka, J.; Sanyal, M.; Aufiero, D.J.; Kitabayashi, I.; Herr, W.; Cleary, M.L. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell. Biol. 2004, 24, 5639–5649. [Google Scholar] [CrossRef] [Green Version]
  28. Hughes, C.M.; Rozenblatt-Rosen, O.; Milne, T.A.; Copeland, T.D.; Levine, S.S.; Lee, J.C.; Hayes, D.N.; Shanmugam, K.S.; Bhattacharjee, A.; Biondi, C.A.; et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol. Cell 2004, 13, 587–597. [Google Scholar] [CrossRef]
  29. Chandrasekharappa, S.C.; Guru, S.C.; Manickam, P.; Olufemi, S.E.; Collins, F.S.; Emmert-Buck, M.R.; Debelenko, L.V.; Zhuang, Z.; Lubensky, I.A.; Liotta, L.A.; et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997, 276, 404–407. [Google Scholar] [CrossRef]
  30. McDonnell, J.E.; Gild, M.L.; Clifton-Bligh, R.J.; Robinson, B.G. Multiple endocrine neoplasia: An update. Intern. Med. J. 2019, 49, 954–961. [Google Scholar] [CrossRef]
  31. Larsson, C.; Skogseid, B.; Oberg, K.; Nakamura, Y.; Nordenskjold, M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988, 332, 85–87. [Google Scholar] [CrossRef] [PubMed]
  32. Metz, D.C.; Jensen, R.T. Gastrointestinal neuroendocrine tumors: Pancreatic endocrine tumors. Gastroenterology 2008, 135, 1469–1492. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Mulvey, C.K.; Van Loon, K.; Bergsland, E.K.; Masharani, U.; Nakakura, E.K. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Pancreas 2017, 46, 416–426. [Google Scholar] [CrossRef] [PubMed]
  34. Tatsi, C.; Stratakis, C.A. The Genetics of Pituitary Adenomas. J. Clin. Med. 2019, 9, 30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Ito, T.; Igarashi, H.; Uehara, H.; Berna, M.J.; Jensen, R.T. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: A Prospective study: Comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine 2013, 92, 135–181. [Google Scholar] [CrossRef]
  36. Agarwal, S.K. Multiple endocrine neoplasia type 1. Front. Horm Res. 2013, 41, 1–15. [Google Scholar] [CrossRef]
  37. Yokoyama, A.; Somervaille, T.C.; Smith, K.S.; Rozenblatt-Rosen, O.; Meyerson, M.; Cleary, M.L. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005, 123, 207–218. [Google Scholar] [CrossRef]
  38. Chen, Y.X.; Yan, J.; Keeshan, K.; Tubbs, A.T.; Wang, H.; Silva, A.; Brown, E.J.; Hess, J.L.; Pear, W.S.; Hua, X. The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc. Natl. Acad. Sci. USA 2006, 103, 1018–1023. [Google Scholar] [CrossRef] [Green Version]
  39. Cierpicki, T.; Grembecka, J. Challenges and opportunities in targeting the menin-MLL interaction. Future Med. Chem. 2014, 6, 447–462. [Google Scholar] [CrossRef] [Green Version]
  40. Zhang, P.; Bergamin, E.; Couture, J.F. The many facets of MLL1 regulation. Biopolymers 2013, 99, 136–145. [Google Scholar] [CrossRef]
  41. Uchino, S.; Noguchi, S.; Sato, M.; Yamashita, H.; Yamashita, H.; Watanabe, S.; Murakami, T.; Toda, M.; Ohshima, A.; Futata, T.; et al. Screening of the Men1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. Cancer Res. 2000, 60, 5553–5557. [Google Scholar] [PubMed]
  42. Lemos, M.C.; Thakker, R.V. Multiple endocrine neoplasia type 1 (MEN1): Analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat. 2008, 29, 22–32. [Google Scholar] [CrossRef] [PubMed]
  43. Lemmens, I.; Van de Ven, W.J.; Kas, K.; Zhang, C.X.; Giraud, S.; Wautot, V.; Buisson, N.; De Witte, K.; Salandre, J.; Lenoir, G.; et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum. Mol. Genet. 1997, 6, 1177–1183. [Google Scholar] [CrossRef] [PubMed]
  44. Agarwal, S.K.; Kester, M.B.; Debelenko, L.V.; Heppner, C.; Emmert-Buck, M.R.; Skarulis, M.C.; Doppman, J.L.; Kim, Y.S.; Lubensky, I.A.; Zhuang, Z.; et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum. Mol. Genet. 1997, 6, 1169–1175. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Kamilaris, C.D.C.; Stratakis, C.A. Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis. Front. Endocrinol. 2019, 10, 339. [Google Scholar] [CrossRef] [Green Version]
  46. Bergman, L.; Boothroyd, C.; Palmer, J.; Grimmond, S.; Walters, M.; Teh, B.; Shepherd, J.; Hartley, L.; Hayward, N. Identification of somatic mutations of the MEN1 gene in sporadic endocrine tumours. Br. J. Cancer 2000, 83, 1003–1008. [Google Scholar] [CrossRef]
  47. Thakker, R.V. Multiple endocrine neoplasia type 1 (MEN1). Best Pract. Res. Clin. Endocrinol. Metab. 2010, 24, 355–370. [Google Scholar] [CrossRef]
  48. Machens, A.; Schaaf, L.; Karges, W.; Frank-Raue, K.; Bartsch, D.K.; Rothmund, M.; Schneyer, U.; Goretzki, P.; Raue, F.; Dralle, H. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): A multicentre study of 258 gene carriers. Clin. Endocrinol. 2007, 67, 613–622. [Google Scholar] [CrossRef]
  49. Marini, F.; Giusti, F.; Fossi, C.; Cioppi, F.; Cianferotti, L.; Masi, L.; Boaretto, F.; Zovato, S.; Cetani, F.; Colao, A.; et al. Multiple endocrine neoplasia type 1: Analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. Endocrine 2018, 62, 215–233. [Google Scholar] [CrossRef] [Green Version]
  50. Wautot, V.; Vercherat, C.; Lespinasse, J.; Chambe, B.; Lenoir, G.M.; Zhang, C.X.; Porchet, N.; Cordier, M.; Beroud, C.; Calender, A. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: Search for correlation between phenotype and the functional domains of the MEN1 protein. Hum. Mutat. 2002, 20, 35–47. [Google Scholar] [CrossRef]
  51. Kovesdi, A.; Toth, M.; Butz, H.; Szucs, N.; Sarman, B.; Pusztai, P.; Toke, J.; Reismann, P.; Faklya, M.; Toth, G.; et al. True MEN1 or phenocopy? Evidence for geno-phenotypic correlations in MEN1 syndrome. Endocrine 2019, 65, 451–459. [Google Scholar] [CrossRef] [Green Version]
  52. Iacovazzo, D.; Hernandez-Ramirez, L.C.; Korbonits, M. Sporadic pituitary adenomas: The role of germline mutations and recommendations for genetic screening. Expert Rev. Endocrinol. Metab. 2017, 12, 143–153. [Google Scholar] [CrossRef] [PubMed]
  53. Ullmann, U.; Unuane, D.; Velkeniers, B.; Lissens, W.; Wuyts, W.; Bonduelle, M. A new double substitution mutation in the MEN1 gene: A limited penetrance and a specific phenotype. Eur. J. Hum. Genet. 2013, 21, 695–697. [Google Scholar] [CrossRef]
  54. Dreijerink, K.M.; van Beek, A.P.; Lentjes, E.G.; Post, J.G.; van der Luijt, R.B.; Canninga-van Dijk, M.R.; Lips, C.J. Acromegaly in a multiple endocrine neoplasia type 1 (MEN1) family with low penetrance of the disease. Eur. J. Endocrinol. 2005, 153, 741–746. [Google Scholar] [CrossRef]
  55. Weinhausel, A.; Kaserer, K.; Vierhapper, H.; Niederle, B.; Haas, O.A.; Study Group of Multiple Endocrine Neoplasia, A. Multiple endocrine neoplasia type 1 (MEN1) in Austria. Wien. Klin. Wochenschr. 2002, 114, 252–257. [Google Scholar] [PubMed]
  56. Giraud, S.; Zhang, C.X.; Serova-Sinilnikova, O.; Wautot, V.; Salandre, J.; Buisson, N.; Waterlot, C.; Bauters, C.; Porchet, N.; Aubert, J.P.; et al. Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. Am. J. Hum. Genet. 1998, 63, 455–467. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Trump, D.; Farren, B.; Wooding, C.; Pang, J.T.; Besser, G.M.; Buchanan, K.D.; Edwards, C.R.; Heath, D.A.; Jackson, C.E.; Jansen, S.; et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 1996, 89, 653–669. [Google Scholar] [CrossRef]
  58. Walls, G.V. Multiple endocrine neoplasia (MEN) syndromes. Semin. Pediatr. Surg. 2014, 23, 96–101. [Google Scholar] [CrossRef]
  59. Tate, J.G.; Bamford, S.; Jubb, H.C.; Sondka, Z.; Beare, D.M.; Bindal, N.; Boutselakis, H.; Cole, C.G.; Creatore, C.; Dawson, E.; et al. COSMIC: The Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019, 47, D941–D947. [Google Scholar] [CrossRef] [Green Version]
  60. Papadopoulos, J.S.; Agarwala, R. COBALT: Constraint-based alignment tool for multiple protein sequences. Bioinformatics 2007, 23, 1073–1079. [Google Scholar] [CrossRef] [Green Version]
  61. Douville, C.; Carter, H.; Kim, R.; Niknafs, N.; Diekhans, M.; Stenson, P.D.; Cooper, D.N.; Ryan, M.; Karchin, R. CRAVAT: Cancer-related analysis of variants toolkit. Bioinformatics 2013, 29, 647–648. [Google Scholar] [CrossRef] [PubMed]
  62. Douville, C.; Masica, D.L.; Stenson, P.D.; Cooper, D.N.; Gygax, D.M.; Kim, R.; Ryan, M.; Karchin, R. Assessing the Pathogenicity of Insertion and Deletion Variants with the Variant Effect Scoring Tool (VEST-Indel). Hum. Mutat. 2016, 37, 28–35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Carter, H.; Chen, S.; Isik, L.; Tyekucheva, S.; Velculescu, V.E.; Kinzler, K.W.; Vogelstein, B.; Karchin, R. Cancer-specific high-throughput annotation of somatic mutations: Computational prediction of driver missense mutations. Cancer Res. 2009, 69, 6660–6667. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Carter, H.; Douville, C.; Stenson, P.D.; Cooper, D.N.; Karchin, R. Identifying Mendelian disease genes with the variant effect scoring tool. BMC Genom. 2013, 14 (Suppl. S3). [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Jay, J.J.; Brouwer, C. Lollipops in the Clinic: Information Dense Mutation Plots for Precision Medicine. PLoS ONE 2016, 11, e0160519. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Perrier, N.D. From Initial Description by Wermer to Present-Day MEN1: What have We Learned? World J. Surg. 2018, 42, 1031–1035. [Google Scholar] [CrossRef] [PubMed]
  67. Khodaei-O’Brien, S.; Zablewska, B.; Fromaget, M.; Bylund, L.; Weber, G.; Gaudray, P. Heterogeneity at the 5’-end of MEN1 transcripts. Biochem. Biophys. Res. Commun. 2000, 276, 508–514. [Google Scholar] [CrossRef] [PubMed]
  68. Forsberg, L.; Zablewska, B.; Piehl, F.; Weber, G.; Lagercrantz, S.; Gaudray, P.; Hoog, C.; Larsson, C. Differential expression of multiple alternative spliceforms of the Men1 tumor suppressor gene in mouse. Int. J. Mol. Med. 2001, 8, 681–689. [Google Scholar] [CrossRef] [PubMed]
  69. Ehrlich, L.; Hall, C.; Meng, F.; Lairmore, T.; Alpini, G.; Glaser, S. A Review of the Scaffold Protein Menin and its Role in Hepatobiliary Pathology. Gene Expr. 2017, 17, 251–263. [Google Scholar] [CrossRef] [PubMed]
  70. den Dunnen, J.T.; Dalgleish, R.; Maglott, D.R.; Hart, R.K.; Greenblatt, M.S.; McGowan-Jordan, J.; Roux, A.F.; Smith, T.; Antonarakis, S.E.; Taschner, P.E. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Hum. Mutat. 2016, 37, 564–569. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  71. Dalgleish, R.; Flicek, P.; Cunningham, F.; Astashyn, A.; Tully, R.E.; Proctor, G.; Chen, Y.; McLaren, W.M.; Larsson, P.; Vaughan, B.W.; et al. Locus Reference Genomic sequences: An improved basis for describing human DNA variants. Genome Med. 2010, 2, 24. [Google Scholar] [CrossRef]
  72. MacArthur, J.A.; Morales, J.; Tully, R.E.; Astashyn, A.; Gil, L.; Bruford, E.A.; Larsson, P.; Flicek, P.; Dalgleish, R.; Maglott, D.R.; et al. Locus Reference Genomic: Reference sequences for the reporting of clinically relevant sequence variants. Nucleic Acids Res. 2014, 42, D873–D878. [Google Scholar] [CrossRef]
  73. Marhuenda, Y.; Morales, D.; Pardo, M.C. A comparison of uniformity tests. Statistics 2005, 39, 315–327. [Google Scholar] [CrossRef]
  74. Falchetti, A. Genetics of multiple endocrine neoplasia type 1 syndrome: What’s new and what’s old. F1000Research 2017, 6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Brule, C.E.; Grayhack, E.J. Synonymous Codons: Choose Wisely for Expression. Trends Genet. 2017, 33, 283–297. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Wu, T.; Zhang, X.; Huang, X.; Yang, Y.; Hua, X. Regulation of cyclin B2 expression and cell cycle G2/m transition by menin. J. Biol. Chem. 2010, 285, 18291–18300. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Muhammad, A.B.; Xing, B.; Liu, C.; Naji, A.; Ma, X.; Simmons, R.A.; Hua, X. Menin and PRMT5 suppress GLP1 receptor transcript and PKA-mediated phosphorylation of FOXO1 and CREB. Am. J. Physiol. Endocrinol. Metab. 2017, 313, E148–E166. [Google Scholar] [CrossRef] [PubMed]
  78. Tanaka, C.; Yoshimoto, K.; Yamada, S.; Nishioka, H.; Ii, S.; Moritani, M.; Yamaoka, T.; Itakura, M. Absence of germ-line mutations of the multiple endocrine neoplasia type 1 (MEN1) gene in familial pituitary adenoma in contrast to MEN1 in Japanese. J. Clin. Endocrinol. Metab. 1998, 83, 960–965. [Google Scholar] [CrossRef] [PubMed]
  79. Yaguchi, H.; Ohkura, N.; Takahashi, M.; Nagamura, Y.; Kitabayashi, I.; Tsukada, T. Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Mol. Cell. Biol. 2004, 24, 6569–6580. [Google Scholar] [CrossRef] [Green Version]
  80. Heppner, C.; Kester, M.B.; Agarwal, S.K.; Debelenko, L.V.; Emmert-Buck, M.R.; Guru, S.C.; Manickam, P.; Olufemi, S.E.; Skarulis, M.C.; Doppman, J.L.; et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nat. Genet. 1997, 16, 375–378. [Google Scholar] [CrossRef]
  81. Cinque, L.; Sparaneo, A.; Salcuni, A.S.; de Martino, D.; Battista, C.; Logoluso, F.; Palumbo, O.; Cocchi, R.; Maiello, E.; Graziano, P.; et al. MEN1 gene mutation with parathyroid carcinoma: First report of a familial case. Endocr. Connect. 2017, 6, 886–891. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  82. Zehir, A.; Benayed, R.; Shah, R.H.; Syed, A.; Middha, S.; Kim, H.R.; Srinivasan, P.; Gao, J.; Chakravarty, D.; Devlin, S.M.; et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 2017, 23, 703–713. [Google Scholar] [CrossRef] [PubMed]
  83. Jiao, Y.; Shi, C.; Edil, B.H.; de Wilde, R.F.; Klimstra, D.S.; Maitra, A.; Schulick, R.D.; Tang, L.H.; Wolfgang, C.L.; Choti, M.A.; et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011, 331, 1199–1203. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Fujii, T.; Kawai, T.; Saito, K.; Hishima, T.; Hayashi, Y.; Imura, J.; Hironaka, M.; Hosoya, Y.; Koike, M.; Fukayama, M. MEN1 gene mutations in sporadic neuroendocrine tumors of foregut derivation. Pathol. Int. 1999, 49, 968–973. [Google Scholar] [CrossRef] [PubMed]
  85. Zhuang, Z.; Vortmeyer, A.O.; Pack, S.; Huang, S.; Pham, T.A.; Wang, C.; Park, W.S.; Agarwal, S.K.; Debelenko, L.V.; Kester, M.; et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res. 1997, 57, 4682–4686. [Google Scholar] [PubMed]
  86. Asteria, C.; Anagni, M.; Fugazzola, L.; Faglia, G.; Vezzadini, P.; Beck-Peccoz, P. MEN1 gene mutations are a rare event in patients with sporadic neuroendocrine tumors. Eur. J. Intern. Med. 2002, 13, 319–323. [Google Scholar] [CrossRef]
  87. Alvelos, M.I.; Vinagre, J.; Fonseca, E.; Barbosa, E.; Teixeira-Gomes, J.; Sobrinho-Simoes, M.; Soares, P. MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism. Eur. J. Endocrinol. 2013, 168, 119–128. [Google Scholar] [CrossRef] [Green Version]
  88. Swarts, D.R.; Scarpa, A.; Corbo, V.; Van Criekinge, W.; van Engeland, M.; Gatti, G.; Henfling, M.E.; Papotti, M.; Perren, A.; Ramaekers, F.C.; et al. MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids. J. Clin. Endocrinol. Metab. 2014, 99, E374–E378. [Google Scholar] [CrossRef] [Green Version]
  89. Wang, E.H.; Ebrahimi, S.A.; Wu, A.Y.; Kashefi, C.; Passaro, E., Jr.; Sawicki, M.P. Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res. 1998, 58, 4417–4420. [Google Scholar]
  90. Totoki, Y.; Yoshida, A.; Hosoda, F.; Nakamura, H.; Hama, N.; Ogura, K.; Yoshida, A.; Fujiwara, T.; Arai, Y.; Toguchida, J.; et al. Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma. Genome Res. 2014, 24, 1411–1420. [Google Scholar] [CrossRef] [Green Version]
  91. Pantaleo, M.A.; Urbini, M.; Indio, V.; Ravegnini, G.; Nannini, M.; De Luca, M.; Tarantino, G.; Angelini, S.; Gronchi, A.; Vincenzi, B.; et al. Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. Mol. Cancer Res. 2017, 15, 553–562. [Google Scholar] [CrossRef] [Green Version]
  92. Kan, Z.; Jaiswal, B.S.; Stinson, J.; Janakiraman, V.; Bhatt, D.; Stern, H.M.; Yue, P.; Haverty, P.M.; Bourgon, R.; Zheng, J.; et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466, 869–873. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Shi, J.; Hua, X.; Zhu, B.; Ravichandran, S.; Wang, M.; Nguyen, C.; Brodie, S.A.; Palleschi, A.; Alloisio, M.; Pariscenti, G.; et al. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study. PLoS Med. 2016, 13, e1002162. [Google Scholar] [CrossRef] [PubMed]
  94. Tanaka, C.; Uchino, S.; Noguchi, S.; Nishioka, T.; Yamasaki, H.; Hashimoto, K.; Yoshimoto, K. Biallelic inactivation by somatic mutations of the MEN1 gene in sporadic parathyroid tumors. Cancer Lett. 2002, 175, 175–179. [Google Scholar] [CrossRef]
  95. Fernandez-Cuesta, L.; Peifer, M.; Lu, X.; Sun, R.; Ozretic, L.; Seidal, D.; Zander, T.; Leenders, F.; George, J.; Muller, C.; et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat. Commun. 2014, 5, 3518. [Google Scholar] [CrossRef] [PubMed]
  96. Leclercq, S.; Rivals, E.; Jarne, P. DNA slippage occurs at microsatellite loci without minimal threshold length in humans: A comparative genomic approach. Genome Biol. Evol. 2010, 2, 325–335. [Google Scholar] [CrossRef] [Green Version]
  97. Ross, J.S.; Gay, L.M.; Wang, K.; Ali, S.M.; Chumsri, S.; Elvin, J.A.; Bose, R.; Vergilio, J.A.; Suh, J.; Yelensky, R.; et al. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. Cancer 2016, 122, 2654–2662. [Google Scholar] [CrossRef]
  98. Ross, J.S.; Wang, K.; Sheehan, C.E.; Boguniewicz, A.B.; Otto, G.; Downing, S.R.; Sun, J.; He, J.; Curran, J.A.; Ali, S.; et al. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin. Cancer Res. 2013, 19, 2668–2676. [Google Scholar] [CrossRef] [Green Version]
  99. Lippert, J.; Appenzeller, S.; Liang, R.; Sbiera, S.; Kircher, S.; Altieri, B.; Nanda, I.; Weigand, I.; Gehrig, A.; Steinhauer, S.; et al. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. J. Clin. Endocrinol. Metab. 2018, 103, 4511–4523. [Google Scholar] [CrossRef]
  100. Cromer, M.K.; Starker, L.F.; Choi, M.; Udelsman, R.; Nelson-Williams, C.; Lifton, R.P.; Carling, T. Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. J. Clin. Endocrinol. Metab. 2012, 97, E1774–E1781. [Google Scholar] [CrossRef] [Green Version]
  101. Goebel, S.U.; Heppner, C.; Burns, A.L.; Marx, S.J.; Spiegel, A.M.; Zhuang, Z.; Lubensky, I.A.; Gibril, F.; Jensen, R.T.; Serrano, J. Genotype/phenotype correlation of multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas. J. Clin. Endocrinol. Metab. 2000, 85, 116–123. [Google Scholar] [CrossRef] [PubMed]
  102. Pardi, E.; Marcocci, C.; Borsari, S.; Saponaro, F.; Torregrossa, L.; Tancredi, M.; Raspini, B.; Basolo, F.; Cetani, F. Aryl hydrocarbon receptor interacting protein (AIP) mutations occur rarely in sporadic parathyroid adenomas. J. Clin. Endocrinol. Metab. 2013, 98, 2800–2810. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  103. Cetani, F.; Pardi, E.; Giovannetti, A.; Cerrai, P.; Borsari, S.; Vignali, E.; Picone, A.; Cianferotti, L.; Miccoli, P.; Pinchera, A.; et al. Six novel MEN1 gene mutations in sporadic parathyroid tumors. Hum. Mutat. 2000, 16, 445. [Google Scholar] [CrossRef]
  104. Taylor, B.S.; Schultz, N.; Hieronymus, H.; Gopalan, A.; Xiao, Y.; Carver, B.S.; Arora, V.K.; Kaushik, P.; Cerami, E.; Reva, B.; et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18, 11–22. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  105. Ferrari, A.; Vincent-Salomon, A.; Pivot, X.; Sertier, A.S.; Thomas, E.; Tonon, L.; Boyault, S.; Mulugeta, E.; Treilleux, I.; MacGrogan, G.; et al. A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. Nat. Commun. 2016, 7, 12222. [Google Scholar] [CrossRef] [PubMed]
  106. Schulte, K.M.; Mengel, M.; Heinze, M.; Simon, D.; Scheuring, S.; Kohrer, K.; Roher, H.D. Complete sequencing and messenger ribonucleic acid expression analysis of the MEN I gene in adrenal cancer. J. Clin. Endocrinol. Metab. 2000, 85, 441–448. [Google Scholar] [CrossRef]
  107. Landa, I.; Ibrahimpasic, T.; Boucai, L.; Sinha, R.; Knauf, J.A.; Shah, R.H.; Dogan, S.; Ricarte-Filho, J.C.; Krishnamoorthy, G.P.; Xu, B.; et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Investig. 2016, 126, 1052–1066. [Google Scholar] [CrossRef] [Green Version]
  108. Dutton-Regester, K.; Kakavand, H.; Aoude, L.G.; Stark, M.S.; Gartside, M.G.; Johansson, P.; O’Connor, L.; Lanagan, C.; Tembe, V.; Pupo, G.M.; et al. Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. Pigment. Cell Melanoma Res. 2013, 26, 852–860. [Google Scholar] [CrossRef]
  109. Prostatic intraepithelial neoplasia: Significance and correlation with prostate-specific antigen and transrectal ultrasound. Proceedings of a workshop of the National Prostate Cancer Detection Project. March 13, 1989, Bethesda, Maryland. Urology 1989, 34, 2–69.
  110. Hyman, D.M.; Piha-Paul, S.A.; Won, H.; Rodon, J.; Saura, C.; Shapiro, G.I.; Juric, D.; Quinn, D.I.; Moreno, V.; Doger, B.; et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 2018, 554, 189–194. [Google Scholar] [CrossRef]
  111. Li, Z.; Razavi, P.; Li, Q.; Toy, W.; Liu, B.; Ping, C.; Hsieh, W.; Sanchez-Vega, F.; Brown, D.N.; Da Cruz Paula, A.F.; et al. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell 2018, 34, 893–905. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  112. Matsumoto, T.; Shimamoto, A.; Goto, M.; Furuichi, Y. Impaired nuclear localization of defective DNA helicases in Werner’s syndrome. Nat. Genet. 1997, 16, 335–336. [Google Scholar] [CrossRef] [PubMed]
  113. Pozdeyev, N.; Gay, L.M.; Sokol, E.S.; Hartmaier, R.; Deaver, K.E.; Davis, S.; French, J.D.; Borre, P.V.; LaBarbera, D.V.; Tan, A.C.; et al. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin. Cancer Res. 2018, 24, 3059–3068. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  114. Wang, K.; Fang, X.; Ma, N.; Lin, Q.; Huang, Z.; Liu, W.; Xu, M.; Chen, X.; Zhang, W.; Zhang, Y. Myeloperoxidase-deficient zebrafish show an augmented inflammatory response to challenge with Candida albicans. Fish. Shellfish Immunol. 2015, 44, 109–116. [Google Scholar] [CrossRef]
  115. Giannakis, M.; Hodis, E.; Jasmine Mu, X.; Yamauchi, M.; Rosenbluh, J.; Cibulskis, K.; Saksena, G.; Lawrence, M.S.; Qian, Z.R.; Nishihara, R.; et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat. Genet. 2014, 46, 1264–1266. [Google Scholar] [CrossRef]
  116. van de Wetering, M.; Francies, H.E.; Francis, J.M.; Bounova, G.; Iorio, F.; Pronk, A.; van Houdt, W.; van Gorp, J.; Taylor-Weiner, A.; Kester, L.; et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015, 161, 933–945. [Google Scholar] [CrossRef] [Green Version]
  117. Liu, Z.; Yang, C.; Li, X.; Luo, W.; Roy, B.; Xiong, T.; Zhang, X.; Yang, H.; Wang, J.; Ye, Z.; et al. The landscape of somatic mutation in sporadic Chinese colorectal cancer. Oncotarget 2018, 9, 27412–27422. [Google Scholar] [CrossRef] [Green Version]
  118. Yaeger, R.; Chatila, W.K.; Lipsyc, M.D.; Hechtman, J.F.; Cercek, A.; Sanchez-Vega, F.; Jayakumaran, G.; Middha, S.; Zehir, A.; Donoghue, M.T.A.; et al. Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell 2018, 33, 125–136.e123. [Google Scholar] [CrossRef]
  119. Chou, W.C.; Lin, P.H.; Yeh, Y.C.; Shyr, Y.M.; Fang, W.L.; Wang, S.E.; Liu, C.Y.; Chang, P.M.; Chen, M.H.; Hung, Y.P.; et al. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. Int. J. Biol. Sci. 2016, 12, 1523–1532. [Google Scholar] [CrossRef] [Green Version]
  120. Kim, T.M.; Jung, S.H.; Kim, M.S.; Baek, I.P.; Park, S.W.; Lee, S.H.; Lee, H.H.; Kim, S.S.; Chung, Y.J.; Lee, S.H. The mutational burdens and evolutionary ages of early gastric cancers are comparable to those of advanced gastric cancers. J. Pathol. 2014, 234, 365–374. [Google Scholar] [CrossRef]
  121. Kakiuchi, M.; Nishizawa, T.; Ueda, H.; Gotoh, K.; Tanaka, A.; Hayashi, A.; Yamamoto, S.; Tatsuno, K.; Katoh, H.; Watanabe, Y.; et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat. Genet. 2014, 46, 583–587. [Google Scholar] [CrossRef] [PubMed]
  122. Debelenko, L.V.; Brambilla, E.; Agarwal, S.K.; Swalwell, J.I.; Kester, M.B.; Lubensky, I.A.; Zhuang, Z.; Guru, S.C.; Manickam, P.; Olufemi, S.E.; et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum. Mol. Genet. 1997, 6, 2285–2290. [Google Scholar] [CrossRef] [PubMed]
  123. Veschi, S.; Lattanzio, R.; Aceto, G.M.; Curia, M.C.; Magnasco, S.; Angelucci, D.; Cama, A.; Piantelli, M.; Battista, P. Alterations of MEN1 and E-cadherin/beta-catenin complex in sporadic pulmonary carcinoids. Int. J. Oncol. 2012, 41, 1221–1228. [Google Scholar] [CrossRef] [PubMed]
  124. Shankar, G.M.; Taylor-Weiner, A.; Lelic, N.; Jones, R.T.; Kim, J.C.; Francis, J.M.; Abedalthagafi, M.; Borges, L.F.; Coumans, J.V.; Curry, W.T.; et al. Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathol. Commun. 2014, 2, 167. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  125. Bazzi, W.; Renon, M.; Vercherat, C.; Hamze, Z.; Lacheretz-Bernigaud, A.; Wang, H.; Blanc, M.; Roche, C.; Calender, A.; Chayvialle, J.A.; et al. MEN1 missense mutations impair sensitization to apoptosis induced by wild-type menin in endocrine pancreatic tumor cells. Gastroenterology 2008, 135, 1698–1709.e1692. [Google Scholar] [CrossRef]
Cancers 12 02616 g001 550
Figure 1. Structure and function of MENIN. (A) Schematic of MENIN highlighting identified domains and functional regions. (B) Relative positions of MENIN interaction proteins mapped on the structure in (A).
Figure 1. Structure and function of MENIN. (A) Schematic of MENIN highlighting identified domains and functional regions. (B) Relative positions of MENIN interaction proteins mapped on the structure in (A).
Cancers 12 02616 g001
Cancers 12 02616 g002 550
Figure 2. Tissue distribution of all MEN1 mutations reported on the Catalogue of Somatic Mutations in Cancer (COSMIC). (A) Frequency histogram of COSMIC mutations by tissue. (B) Distribution of COSMIC MEN1 mutations by mutation type. Splice site/intronic category also includes 5’ and 3’ untranslated regions (UTRs).
Figure 2. Tissue distribution of all MEN1 mutations reported on the Catalogue of Somatic Mutations in Cancer (COSMIC). (A) Frequency histogram of COSMIC mutations by tissue. (B) Distribution of COSMIC MEN1 mutations by mutation type. Splice site/intronic category also includes 5’ and 3’ untranslated regions (UTRs).
Cancers 12 02616 g002
Cancers 12 02616 g003 550
Figure 3. Open reading frame positions of ClinVar and COSMIC mutations. (A) Counts of unique residue mutation positions by mutation type. (B) Distribution histograms showing Kolmogorov–Smirnov P-values for uniformity. For COSMIC, only the 548 unique residues were mapped. (C) Histogram showing all COSMIC missense, nonsense, frameshift, and indel mutations (including duplicate) to identify hotspots. The mutations generating the three hotspots are shown.
Figure 3. Open reading frame positions of ClinVar and COSMIC mutations. (A) Counts of unique residue mutation positions by mutation type. (B) Distribution histograms showing Kolmogorov–Smirnov P-values for uniformity. For COSMIC, only the 548 unique residues were mapped. (C) Histogram showing all COSMIC missense, nonsense, frameshift, and indel mutations (including duplicate) to identify hotspots. The mutations generating the three hotspots are shown.
Cancers 12 02616 g003
Cancers 12 02616 g004 550
Figure 4. Germline mutations detected in pancreatic, parathyroid, thyroid, pituitary, and thymus cancers. (A) Distribution of germline mutations that appear on COSMIC. The top diagram shows missense and nonsense mutations and bottom diagram shows frameshifts and InDels. (B) Variant Effect Scoring Tool (VEST) and Cancer-Specific High Throughput Annotation of Somatic Mutations (CHASM) p-values of mutations in (A). For most frameshift mutations, p-values could not be calculated.
Figure 4. Germline mutations detected in pancreatic, parathyroid, thyroid, pituitary, and thymus cancers. (A) Distribution of germline mutations that appear on COSMIC. The top diagram shows missense and nonsense mutations and bottom diagram shows frameshifts and InDels. (B) Variant Effect Scoring Tool (VEST) and Cancer-Specific High Throughput Annotation of Somatic Mutations (CHASM) p-values of mutations in (A). For most frameshift mutations, p-values could not be calculated.
Cancers 12 02616 g004
Cancers 12 02616 g005 550
Figure 5. Germline mutations detected in somatic cancers. (A) Distribution of all germline mutations that appear on COSMIC. For completion, substitutions and non-sense mutations in pancreas, parathyroid, thyroid, pituitary, and thymus (from Figure 2A) are also shown, but they are not labeled. Only mutations with a significant VEST or CHASM p-value are shown. (B) CHASM and VEST p-values for the listed substitutions and non-sense mutations. Calculations for most frameshift and indels were not possible. Only I85fs values were calculated. Probability and False Discovery Rate (FDR) values for mutations already shown in Figure 4B have been excluded.
Figure 5. Germline mutations detected in somatic cancers. (A) Distribution of all germline mutations that appear on COSMIC. For completion, substitutions and non-sense mutations in pancreas, parathyroid, thyroid, pituitary, and thymus (from Figure 2A) are also shown, but they are not labeled. Only mutations with a significant VEST or CHASM p-value are shown. (B) CHASM and VEST p-values for the listed substitutions and non-sense mutations. Calculations for most frameshift and indels were not possible. Only I85fs values were calculated. Probability and False Discovery Rate (FDR) values for mutations already shown in Figure 4B have been excluded.
Cancers 12 02616 g005
Cancers 12 02616 g006 550
Figure 6. MEN1 mutations in primary cancers. (A) Distribution of all germline mutations that appear in TCGA samples of primary cancer sites. The legend explaining the color-coding scheme is shown below the diagram. ClinVar does not give the exact frameshift mutation, but, if a frameshift is indicated at the same residue, we assumed it to be identical. (B,C) CHASM, VEST p-values, and tissue distribution for the mutations shown in (A). The same color-coding scheme as in (A) is observed. Pie charts summarize the data in the tables.
Figure 6. MEN1 mutations in primary cancers. (A) Distribution of all germline mutations that appear in TCGA samples of primary cancer sites. The legend explaining the color-coding scheme is shown below the diagram. ClinVar does not give the exact frameshift mutation, but, if a frameshift is indicated at the same residue, we assumed it to be identical. (B,C) CHASM, VEST p-values, and tissue distribution for the mutations shown in (A). The same color-coding scheme as in (A) is observed. Pie charts summarize the data in the tables.
Cancers 12 02616 g006
Table
Table 1. Coordinates and functions of MEN1 domains and interacting proteins.
Table 1. Coordinates and functions of MEN1 domains and interacting proteins.
Gene or RegionMEN1 Coordinates (Amino Acids)Function
MEN1 Domains
NTD1–100Crystal structure identified domain
Thumb101–1230Crystal structure identified domain
Palm231–1300Crystal structure identified domain
Fingers301–1305Crystal structure identified domain
NLS1479–1497Nuclear localization sequence
NLS2588–1608Nuclear localization sequence
NLS3546–1672Nuclear localization sequence
NES133–151Nuclear exit sequence
NES2253–1267Nuclear exit sequence
MEN1 Interacting Proteins
KMTA2 (MLL1)~230–1300Mixed lineage leukemia
LEDGF~1–1100Chromatin associated factor, required for MLL oncogenic transformation
JunD1–140, 323–1448Transcriptional activator, subunit of AP-1 transcription complex
HLXB941–1177, 323?Homeobox gene involved in pancreas development, neural motor protein
SMAD341–1278, 477–1615TGFB signaling pathway, cell proliferation, transcriptional regulation
MYC360-615 (fingers), maybe NTDTranscriptional regulation, cell cycle, apoptosis, cellular transformation
PEM (mouse)278–1476Homeobox gene, embryonic and placenta expression
NF-kB subunits305–1476Transcriptional regulators, inflammation, immune response, cell proliferation
SIRT1305–1476Sirtuitin, gene silencing
SIN3A295–1450Gene expression regulator, embryogenesis, cell proliferation, senescence
HDAC1295–1450Histone deacetylase, transcriptional regulator, cell proliferation and differentiation
PRMT5L22, A242Arginine methyltransferase, transcriptional regulation, DNA damage repair
FANCD2219–1395Fancomi anemia complex subunit, DNA damage repair
RPA21–140, 286–1448Replication Protein A subunit
Table
Table 2. MEN1 transcript variants and their corresponding MENIN protein isoforms.
Table 2. MEN1 transcript variants and their corresponding MENIN protein isoforms.
1 Transcript VariantTranscript Size (Bases)Protein IsoformProtein Size (Amino Acids)
127852 1615
e1B27481615
e1C27361615
e1D37121615
e1E31791615
e1F130151615
227703 2610
328283652
427122610
527022610
629602610
728554575
826094575
4 MEN1-20731502610
5 MEN1-2052868?555
X13629X1657
X236293652
6 Isoform alignment schematic.
Cancers 12 02616 i001
1 The names and sizes of variants and isoforms are from NCBI. 2 This is one of the two major isoforms of MENIN. 3 This is another of the two major isoforms of MENIN. 4 This variant refers to transcript ENST0000377326.7 but does not have a corresponding variant name on NCBI. It is listed as Men1-207 on Ensembl. 5 This variant refers to transcript ENST0000377316.6 but does not have a corresponding variant name on NCBI. It is listed as MEN1-205 on Ensemble. 6 This is a schematic diagram generated by COBALT showing the size differences of the various MENIN isoforms. For amino acid alignment, please see Figure S1.

Share and Cite

MDPI and ACS Style

Nelakurti, D.D.; Pappula, A.L.; Rajasekaran, S.; Miles, W.O.; Petreaca, R.C. Comprehensive Analysis of MEN1 Mutations and Their Role in Cancer. Cancers 2020, 12, 2616. https://doi.org/10.3390/cancers12092616

AMA Style

Nelakurti DD, Pappula AL, Rajasekaran S, Miles WO, Petreaca RC. Comprehensive Analysis of MEN1 Mutations and Their Role in Cancer. Cancers. 2020; 12(9):2616. https://doi.org/10.3390/cancers12092616

Chicago/Turabian Style

Nelakurti, Devi D., Amrit L. Pappula, Swetha Rajasekaran, Wayne O. Miles, and Ruben C. Petreaca. 2020. "Comprehensive Analysis of MEN1 Mutations and Their Role in Cancer" Cancers 12, no. 9: 2616. https://doi.org/10.3390/cancers12092616

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop